Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Significant Drop in Short Interest

Candel Therapeutics, Inc. (NASDAQ:CADL) was the recipient of a significant drop in short interest in June. As of June 15th, there was short interest totalling 1,060,000 shares, a drop of 31.6% from the May 31st total of 1,550,000 shares. Based on an average daily trading volume, of 5,620,000 shares, the short-interest ratio is presently 0.2 days. Currently, 5.6% of the company’s stock are sold short.

Candel Therapeutics Stock Up 5.3 %

NASDAQ CADL traded up $0.31 during trading hours on Friday, hitting $6.20. The company’s stock had a trading volume of 3,588,472 shares, compared to its average volume of 482,306. The company has a market capitalization of $184.51 million, a PE ratio of -4.84 and a beta of -0.84. The company has a current ratio of 2.00, a quick ratio of 2.00 and a debt-to-equity ratio of 1.66. Candel Therapeutics has a 52 week low of $0.66 and a 52 week high of $14.30. The company’s 50-day simple moving average is $8.22 and its two-hundred day simple moving average is $4.17.

Candel Therapeutics (NASDAQ:CADL) last released its quarterly earnings results on Tuesday, May 14th. The company reported ($0.28) earnings per share for the quarter. Research analysts anticipate that Candel Therapeutics will post -0.91 EPS for the current fiscal year.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.